Metabolic Oncolytic Regimne

The Metabolic Oncolytic Regimen is based on an approach to achieving lysis or die-off in solid tumors pioneered by NASA scientist Clarence Cone, Jr., Ph.D. (Deceased). Dr. Cone's novel therapy, which is reflected in patents granted various versions of same [U.S. patent #s 4,724,230 (1988), 4,724,234 (1988), and 4,935,450 (1990)] essentially involves manipulating various metabolic and biochemical pathways such that tumors produce prodigous quantities of lactic acid. This is achieved using a specific dietary regimen plus various synthetic and natural drugs.

During the late 1980s, biological theoretician Dr. Anthony G. Payne realized that the Cone therapy was deficient insofar as the Cone approach would tend to eradicate hypoxic clusters within certain solid tumors, but not the entire tumor - which synthesizes and exports lactic acid (Something which came to light after Dr. Cone's original patent application was filed). According to Dr. Payne, the Cone therapy was appropriate and quite effective in helping eradicate hypoxic intratumor cell communities, but could not address the lysis or kill-off of the non-hypoxic regions of solid tumors per se. Payne crafted a regimen that would do both which was first utilized by cancer patients during 1990. A notable number of these patients achieved partial or total remission on the regimen. Many are still in remission, some going on over 15 years.

The Regimen itself was distributed freely to patients and oncologists by Dr. Payne. At no time did he make money from its use or from any of the compounds listed in it. This is true to this very day (2008).

After satisfying himself that the MOR was proving effective in at least a subsection of cancer patients, Dr. Payne published the Regimen on the Internet and in such periodicals as the Townsend Letter for Doctors.

During 1996 Dr. Payne’s regimen was incorporated by the NIH’s Center for Alternative & Complementary Medicine in a monograph on the Cone therapy. Subsequently Dr. Payne was contacted by the NIH’s Dr. Li-Chuan Chen and invited to a historic cancer conference held at its headquarters in Bethesda, MD (POMES) as a funded attendee. Dr. Payne accepted and participated in the conference.

During 1996 Dr. Payne published a revised version of the original Metabolic Oncolytic Regmen titled (appropriately) "The Revised Metabolic Oncolytic Regimen." During August 2001 it appear in the Townsend Letter for Doctors as "The Revised Metabolic Oncolytic Regimen for Effecting Lysis in Solid Tumors."

Dr. Payne further refined and expanded the Metabolic Oncolytic Regimen during 2005. It appeared in the journal Medical Hypotheses & Research as PREVENTING METASTASIS AND ACHIEVING ONCOLYSIS IN SOLID TUMORS BY INHIBITING SPECIFIC METALLOPROTEINASES AND MANIPULATING KEY METABOLIC PATHWAYS A. G. PAYNE MED HYPOTHESES RES 2: 553-565.

During 2008 2 papers were published in NATURE that upheld the Warburg Effect, which is part and parcel of the METABOLIC ONCOLYTIC REGIMEN.

Main Menu

See Also

Main Menu